|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.304 SEK | -1.46% |
|
+1.52% | -26.01% |
| 03-26 | Transcript : Vivesto AB - Special Call | |
| 03-07 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
Vivesto AB announced that the acting CEO of the company, Christer Nordstedt, has resigned from his position in order to assume a new role outside of the company. The process of recruiting a permanent CEO has been accelerated. Christer Nordstedt will continue in his current role until 30 November 2022 and will thereafter remain as senior advisor to the company on a consultancy basis.
Christer Nordstedt has been acting CEO since 21 July 2022.
| 1st Jan change | Capi. | |
|---|---|---|
| -26.01% | 15.46M | |
| +38.69% | 728B | |
| +32.60% | 603B | |
| -4.49% | 360B | |
| +20.24% | 332B | |
| +2.12% | 279B | |
| +15.74% | 244B | |
| +7.69% | 207B | |
| -5.44% | 205B | |
| +6.42% | 164B |
VIVESTO AB 
